{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:45:12Z","timestamp":1790023512446,"version":"4.0.1"},"reference-count":91,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:p>Duchenne muscular dystrophy is the most common form of childhood muscular dystrophy. A mutation in the DMD gene disrupts dystrophin (protein) production, causing damage to muscle integrity, weakness, loss of ambulation, and cardiopulmonary compromise by the second decade of life. Life expectancy has improved from mid-teenage years to mid-20s with the use of glucocorticoids and beyond the third decade with ventilator support and multidisciplinary care. However, Duchenne muscular dystrophy is associated with comorbidities and is a fatal disease. Glucocorticoids prolong ambulation, but their side effects are significant. Emerging investigational therapies have surfaced over the past decade and have rapidly been tested in clinical trials. Gene-specific strategies include nonsense readthrough, exon skipping, gene editing, utrophin modulation, and gene replacement. Other mechanisms include muscle regeneration, antioxidants, and antifibrosis and anti-inflammatory pathways. With potential therapies emerging, early diagnosis is needed to initiate treatment early enough to minimize morbidity and mortality. Newborn screening can be used to significantly improve early diagnosis, especially for gene-specific therapeutics.<\/jats:p>","DOI":"10.1542\/peds.2018-0333c","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T08:26:19Z","timestamp":1538382379000},"page":"S5-S16","source":"Crossref","is-referenced-by-count":22,"title":["Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy"],"prefix":"10.1542","volume":"142","author":[{"given":"Fawn","family":"Leigh","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Harvard University, Cambridge, Massachusetts;"},{"name":"Seattle Children's Hospital, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferlini","sequence":"additional","affiliation":[{"name":"University of Ferrara, Ferrara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Biggar","sequence":"additional","affiliation":[{"name":"Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Bushby","sequence":"additional","affiliation":[{"name":"John Walton Centre for Muscular Dystrophy Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Finkel","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health System, Orlando, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Morgenroth","sequence":"additional","affiliation":[{"name":"Children\u2019s National Health System, Washington, District of Columbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, Baltimore, Maryland; and"},{"name":"School of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"issue":"3","key":"2021120817540709600_B1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy.","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"issue":"4","key":"2021120817540709600_B2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/jmg.17.4.245","article-title":"Incidence of Duchenne muscular dystrophy in New South Wales and Australian Capital Territory.","volume":"17","author":"Cowan","year":"1980","journal-title":"J Med Genet"},{"issue":"3","key":"2021120817540709600_B3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker muscular dystrophies in the United States.","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"issue":"10","key":"2021120817540709600_B4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nrm2024","article-title":"Molecular mechanisms of muscular dystrophies: old and new players.","volume":"7","author":"Davies","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2021120817540709600_B5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/0470093765.ch8","article-title":"Muscular dystrophies related to the cytoskeleton\/nuclear envelope.","volume":"264","author":"Nowak","year":"2005","journal-title":"Novartis Found Symp"},{"issue":"7","key":"2021120817540709600_B6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01525003","article-title":"Serum levels of myoglobin and creatine kinase in Duchenne muscular dystrophy.","volume":"59","author":"Kiessling","year":"1981","journal-title":"Klin Wochenschr"},{"issue":"7","key":"2021120817540709600_B7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","article-title":"Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation.","volume":"68","author":"Desguerre","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2021120817540709600_B8","first-page":"184","article-title":"The role of fibrosis in Duchenne muscular dystrophy.","volume":"31","author":"Klingler","year":"2012","journal-title":"Acta Myol"},{"issue":"2","key":"2021120817540709600_B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis.","volume":"214","author":"Wynn","year":"2008","journal-title":"J Pathol"},{"issue":"3","key":"2021120817540709600_B10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","article-title":"Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).","volume":"155","author":"Ciafaloni","year":"2009","journal-title":"J Pediatr"},{"issue":"10","key":"2021120817540709600_B11","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul Disord"},{"issue":"24","key":"2021120817540709600_B12","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne\u2019s muscular dystrophy.","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"issue":"5","key":"2021120817540709600_B13","first-page":"CD003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy.","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021120817540709600_B14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mus.23831","article-title":"Corticosteroids in Duchenne muscular dystrophy: major variations in practice.","volume":"48","author":"Griggs","year":"2013","journal-title":"Muscle Nerve"},{"issue":"1","key":"2021120817540709600_B15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ppul.23215","article-title":"Cardiac phenotype determines survival in Duchenne muscular dystrophy.","volume":"51","author":"Birnkrant","year":"2016","journal-title":"Pediatr Pulmonol"},{"issue":"suppl 2","key":"2021120817540709600_B16","first-page":"e20180333I","article-title":"Cardiac management of the patient with Duchenne muscular dystrophy.","volume":"142","author":"Buddhe","year":"2018","journal-title":"Pediatrics"},{"issue":"4","key":"2021120817540709600_B17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"2021120817540709600_B18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(88)90463-1","article-title":"Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy.","volume":"52","author":"Webster","year":"1988","journal-title":"Cell"},{"issue":"13","key":"2021120817540709600_B19","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00018-016-2132-2","article-title":"Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis.","volume":"73","author":"Cea","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"2021120817540709600_B20","volume-title":"Bayley Scales of Infant and Toddler Development: Administration Manual","author":"Bayley","year":"2006"},{"issue":"6","key":"2021120817540709600_B21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.pediatrneurol.2014.02.006","article-title":"One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development.","volume":"50","author":"Connolly","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"2","key":"2021120817540709600_B22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/0734282906297199","article-title":"Test review: Bayley, N. (2006). Bayley scales of infant and toddler development\u2013third edition. San Antonio, TX: Harcourt Assessment.","volume":"25","author":"Albers","year":"2007","journal-title":"J Psychoeduc Assess"},{"issue":"12","key":"2021120817540709600_B23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","article-title":"Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.","volume":"41","author":"Fenichel","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"2021120817540709600_B24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response.","volume":"48","author":"Griggs","year":"1991","journal-title":"Arch Neurol"},{"issue":"1","key":"2021120817540709600_B25","first-page":"CD003725","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy.","author":"Manzur","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021120817540709600_B26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2021120817540709600_B27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpn.2008.02.006","article-title":"Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.","volume":"13","author":"Mavrogeni","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"2021120817540709600_B28","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.","volume":"45","author":"Koenig","year":"1989","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2021120817540709600_B29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"issue":"6","key":"2021120817540709600_B30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nmd.2010.04.005","article-title":"Best practice guidelines on molecular diagnostics in Duchenne\/Becker muscular dystrophies.","volume":"20","author":"Abbs","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2021120817540709600_B31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/0883073808324770","article-title":"Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy.","volume":"24","author":"Cunniff","year":"2009","journal-title":"J Child Neurol"},{"issue":"1","key":"2021120817540709600_B32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.ejhg.5201916","article-title":"Simultaneous mutation scanning for gross deletions, duplications and point mutations in the DMD gene.","volume":"16","author":"Ashton","year":"2008","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"2021120817540709600_B33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","article-title":"Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression.","volume":"24","author":"Willcocks","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2021120817540709600_B34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.24599","article-title":"Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort.","volume":"79","author":"Willcocks","year":"2016","journal-title":"Ann Neurol"},{"issue":"10","key":"2021120817540709600_B35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.","volume":"13","author":"Aartsma-Rus","year":"2007","journal-title":"RNA"},{"key":"2021120817540709600_B36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-61779-767-5_8","article-title":"Overview on AON design.","volume":"867","author":"Aartsma-Rus","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"10","key":"2021120817540709600_B37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"2021120817540709600_B38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nmd.2013.09.004","article-title":"Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial.","volume":"24","author":"Flanigan","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2021120817540709600_B39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"2021120817540709600_B40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy.","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"2021120817540709600_B41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"2021120817540709600_B42","unstructured":"Food and Drug Administration . FDA news release: FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. 2016. Available at: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm. Accessed November 8, 2017"},{"issue":"4","key":"2021120817540709600_B43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations.","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"4","key":"2021120817540709600_B44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1212\/WNL.57.4.645","article-title":"Diagnosis of Duchenne dystrophy by enhanced detection of small mutations.","volume":"57","author":"Mendell","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"2021120817540709600_B45","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-through strategies for suppression of nonsense mutations in Duchenne\/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).","volume":"25","author":"Finkel","year":"2010","journal-title":"J Child Neurol"},{"issue":"6","key":"2021120817540709600_B46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/1756285610388693","article-title":"Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy.","volume":"3","author":"Malik","year":"2010","journal-title":"Ther Adv Neurol Disorder"},{"issue":"4","key":"2021120817540709600_B47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.","volume":"47","author":"Hirawat","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"2021120817540709600_B48","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nbt0814-706","article-title":"EMA reconsiders \u2018read-through\u2019 drug against Duchenne muscular dystrophy following appeal.","volume":"32","author":"Mullard","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"10101","key":"2021120817540709600_B49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"2021120817540709600_B50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0960-8966(93)90037-K","article-title":"Dystrophin and dystrophin-related proteins: a review of protein and RNA studies.","volume":"3","author":"Love","year":"1993","journal-title":"Neuromuscul Disord"},{"issue":"6404","key":"2021120817540709600_B51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/360591a0","article-title":"Primary structure of dystrophin-related protein.","volume":"360","author":"Tinsley","year":"1992","journal-title":"Nature"},{"issue":"3","key":"2021120817540709600_B52","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0959-437X(93)90124-8","article-title":"Dystrophin and related proteins.","volume":"3","author":"Tinsley","year":"1993","journal-title":"Curr Opin Genet Dev"},{"issue":"5\u20136","key":"2021120817540709600_B53","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0960-8966(93)90111-V","article-title":"Utrophin: a potential replacement for dystrophin?","volume":"3","author":"Tinsley","year":"1993","journal-title":"Neuromuscul Disord"},{"issue":"16","key":"2021120817540709600_B54","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1016\/j.bmcl.2011.06.047","article-title":"Discovery and SAR of 2-arylbenzotriazoles and 2-arylindazoles as potential treatments for Duchenne muscular dystrophy.","volume":"21","author":"De Moor","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"2021120817540709600_B55","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI30556","article-title":"Interplay of IKK\/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.","volume":"117","author":"Acharyya","year":"2007","journal-title":"J Clin Invest"},{"key":"2021120817540709600_B56","first-page":"Unit14.22","article-title":"Quantitative assessment of macrophage functions in repair and fibrosis.","volume":"Chapter 14","author":"Wynn","year":"2011","journal-title":"Curr Protoc Immunol"},{"issue":"9979","key":"2021120817540709600_B57","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2021120817540709600_B58","doi-asserted-by":"crossref","first-page":"17142","DOI":"10.1038\/s41598-017-17496-7","article-title":"Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.","volume":"7","author":"Welch","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"2021120817540709600_B59","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s12079-017-0439-x","article-title":"Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.","volume":"12","author":"Acu\u00f1a","year":"2018","journal-title":"J Cell Commun Signal"},{"issue":"1\u20132","key":"2021120817540709600_B60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2006.03.005","article-title":"Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy.","volume":"175","author":"Andreetta","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2021120817540709600_B61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00441-013-1642-6","article-title":"Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF\/CCN-2).","volume":"353","author":"Morales","year":"2013","journal-title":"Cell Tissue Res"},{"issue":"6","key":"2021120817540709600_B62","doi-asserted-by":"crossref","first-page":"e20856","DOI":"10.1371\/journal.pone.0020856","article-title":"Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.","volume":"6","author":"Bish","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2021120817540709600_B63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1074248410381757","article-title":"Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.","volume":"16","author":"Spurney","year":"2011","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"2021120817540709600_B64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy.","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"3988","key":"2021120817540709600_B65","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.172.3988.1143","article-title":"Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions.","volume":"172","author":"Mendell","year":"1971","journal-title":"Science"},{"issue":"5374","key":"2021120817540709600_B66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/239522a0","article-title":"Increased plasma enzyme concentrations in rats with functional ischaemia of muscle provide a possible model of Duchenne muscular dystrophy.","volume":"239","author":"Mendell","year":"1972","journal-title":"Nature"},{"issue":"8","key":"2021120817540709600_B67","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.1371\/journal.pone.0000806","article-title":"Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.","volume":"2","author":"Asai","year":"2007","journal-title":"PLoS One"},{"issue":"4","key":"2021120817540709600_B68","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy.","volume":"76","author":"Leung","year":"2014","journal-title":"Ann Neurol"},{"issue":"17","key":"2021120817540709600_B69","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"issue":"6628","key":"2021120817540709600_B70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"issue":"6","key":"2021120817540709600_B71","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ana.10385","article-title":"Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.","volume":"52","author":"Wagner","year":"2002","journal-title":"Ann Neurol"},{"issue":"5","key":"2021120817540709600_B72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy.","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"issue":"2","key":"2021120817540709600_B73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"2021120817540709600_B74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-017-0590-8","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial.","volume":"12","author":"Raman","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2021120817540709600_B75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2012.04.078","article-title":"Gene therapy for muscular dystrophy: lessons learned and path forward.","volume":"527","author":"Mendell","year":"2012","journal-title":"Neurosci Lett"},{"issue":"4","key":"2021120817540709600_B76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads.","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol Ther"},{"issue":"5","key":"2021120817540709600_B77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"5","key":"2021120817540709600_B78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.gt.3300407","article-title":"Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability.","volume":"4","author":"Decrouy","year":"1997","journal-title":"Gene Ther"},{"issue":"10","key":"2021120817540709600_B79","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/hmg\/ddl082","article-title":"A highly functional mini-dystrophin\/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.","volume":"15","author":"Li","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"18","key":"2021120817540709600_B80","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/hmg\/ddt224","article-title":"Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.","volume":"22","author":"Zhang","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"15","key":"2021120817540709600_B81","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy.","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"2021120817540709600_B82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-5-45","article-title":"A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.","volume":"5","author":"Rodino-Klapac","year":"2007","journal-title":"J Transl Med"},{"key":"2021120817540709600_B83","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"},{"issue":"6271","key":"2021120817540709600_B84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"issue":"6271","key":"2021120817540709600_B85","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells.","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"issue":"6201","key":"2021120817540709600_B86","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA.","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"issue":"6271","key":"2021120817540709600_B87","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"issue":"4","key":"2021120817540709600_B88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.23819","article-title":"LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.","volume":"73","author":"Flanigan","year":"2013","journal-title":"Ann Neurol"},{"issue":"4","key":"2021120817540709600_B89","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ana.24370","article-title":"Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.","volume":"77","author":"Bello","year":"2015","journal-title":"Ann Neurol"},{"issue":"16","key":"2021120817540709600_B90","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1073\/pnas.1324242111","article-title":"Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair.","volume":"111","author":"Swaggart","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2021120817540709600_B91","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/expphysiol.2013.075887","article-title":"Modifiers of heart and muscle function: where genetics meets physiology.","volume":"99","author":"Swaggart","year":"2014","journal-title":"Exp Physiol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/142\/Supplement_2\/S5\/905113\/peds_20180333c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/142\/Supplement_2\/S5\/905113\/peds_20180333c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T14:34:51Z","timestamp":1693924491000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/142\/Supplement_2\/S5\/11572\/Neurology-Care-Diagnostics-and-Emerging-Therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":91,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2018,10,1]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-0333c","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}